Randall Bateman
Affiliations: | Neurology | Washington University School of Medicine, St. Louis, MO, United States |
Google:
"Randall Bateman"Mean distance: (not calculated yet)
Children
Sign in to add trainee| Chihiro Sato | post-doc | ||
| Norelle C. Wildburger | post-doc | 2015-2019 | Washington University School of Medicine |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Iaccarino L, Llibre-Guerra JJ, McDade E, et al. (2024) Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer's disease. Brain Communications. 6: fcae159 |
| Wagemann O, Liu H, Wang G, et al. (2024) Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial. Jama Neurology |
| Levin J, Baiardi S, Quadalti C, et al. (2024) α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden. Alzheimer's & Dementia : the Journal of the Alzheimer's Association |
| Wisch JK, McKay NS, Boerwinkle AH, et al. (2024) Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study. The Lancet. Neurology. 23: 500-510 |
| Galasko D, Farlow MR, Lucey BP, et al. (2024) A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's Disease. Medrxiv : the Preprint Server For Health Sciences |
| Doering S, McCullough A, Gordon BA, et al. (2024) Deconstructing pathological tau by biological process in early stages of Alzheimer disease: a method for quantifying tau spatial spread in neuroimaging. Ebiomedicine. 103: 105080 |
| Canestaro WJ, Bateman RJ, Holtzman DM, et al. (2024) Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment. Population Health Management |
| Salvadó G, Horie K, Barthélemy NR, et al. (2024) Disease staging of Alzheimer's disease using a CSF-based biomarker model. Nature Aging |
| Meeker KL, Luckett PH, Barthélemy NR, et al. (2024) Comparison of cerebrospinal fluid, plasma and neuroimaging biomarker utility in Alzheimer's disease. Brain Communications. 6: fcae081 |
| Orr M, Garbarino V, Palavicini J, et al. (2024) Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer's Disease. Research Square |